» Articles » PMID: 27317650

NCAM- and FGF-2-mediated FGFR1 Signaling in the Tumor Microenvironment of Esophageal Cancer Regulates the Survival and Migration of Tumor-associated Macrophages and Cancer Cells

Overview
Journal Cancer Lett
Specialty Oncology
Date 2016 Jun 19
PMID 27317650
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) have important roles in the angiogenesis and tumor immunosuppression of various cancers, including esophageal squamous cell carcinomas (ESCCs). To elucidate the roles of TAMs in ESCCs, we compared the gene expression profiles between human peripheral blood monocyte-derived macrophage-like cells (Macrophage_Ls) and Macrophage_Ls stimulated with conditioned medium of the TE series human ESCC cell line (TECM) (TAM_Ls) using cDNA microarray analysis. Among the highly expressed genes in TAM_Ls, we focused on neural cell adhesion molecule (NCAM). NCAM knockdown in TAM_Ls revealed a significant decrease of migration and survival via a suppression of PI3K-Akt and fibroblast growth factor receptor 1 (FGFR1) signaling. Stimulation by TECM up-regulated the level of FGFR1 in Macrophage_Ls. Recombinant human fibroblast growth factor-2 (rhFGF-2) promoted the migration and survival of TAM_Ls and TE-cells through FGFR1 signaling. Our immunohistochemical analysis of 70 surgically resected ESCC samples revealed that the up-regulated FGF-2 in stromal cells, including macrophages, was associated with more aggressive phenotypes and a high number of infiltrating M2 macrophages. These findings may indicate a novel role of NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of ESCCs.

Citing Articles

Isolation and Comprehensive Analysis of Cochlear Tissue-Derived Small Extracellular Vesicles.

Jiang P, Ma X, Wang X, Huang J, Wang Y, Ai J Adv Sci (Weinh). 2024; 11(48):e2408964.

PMID: 39497619 PMC: 11672270. DOI: 10.1002/advs.202408964.


Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases.

Shen L, Li Y, Zhao H Front Immunol. 2024; 15:1390453.

PMID: 38962005 PMC: 11219802. DOI: 10.3389/fimmu.2024.1390453.


Advances in bacteria-based drug delivery systems for anti-tumor therapy.

Shuwen H, Yifei S, Xinyue W, Zhanbo Q, Xiang Y, Xi Y Clin Transl Immunology. 2024; 13(7):e1518.

PMID: 38939727 PMC: 11208082. DOI: 10.1002/cti2.1518.


Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis.

Park J, Lee Y, Ko Y, Park Y, Shin H, Hur M J Liver Cancer. 2024; 24(1):81-91.

PMID: 38246747 PMC: 10990665. DOI: 10.17998/jlc.2023.12.25.


Role of adhesion molecules in cancer and targeted therapy.

Fan C, Xiong F, Zhang S, Gong Z, Liao Q, Li G Sci China Life Sci. 2024; 67(5):940-957.

PMID: 38212458 DOI: 10.1007/s11427-023-2417-3.